Fibrocor Therapeutics is developing first-in-class therapies that target kidney disease at its roots by blocking fibroblast activation and excessive collagen deposition. The company’s lead focus is Alport Syndrome, a severe condition with no disease-modifying treatments, with the goal of delivering life-changing outcomes for patients who often face early dialysis or transplantation. Using a biomarker-driven approach and human biopsy–derived targets, Fibrocor is advancing a deliberate, translatable clinical strategy and aims to seek accelerated approval for its lead program in 2029. Its fibrosis-targeting platform has broad potential across multiple kidney diseases and other organs, powered by a seasoned leadership team, including CEO William Newsome, scientific leader Piet Wigerinck, and clinical expert Paul Ford, with decades of experience in fibrosis biology, drug development, and clinical strategy. Leveraging patient-derived kidney tissue, Fibrocor is also advancing programs in ADPKD and transplant-related fibrosis, identifying precision targets to slow disease progression and preserve long-term organ health